TL;DR: The three leading GLP-1-class peptides for weight-management in the Philippines today are Tirzepatide (dual GIP/GLP-1 agonist), Retatrutide (triple GIP/GLP-1/glucagon agonist), and Cagrilintide (long-acting amylin analogue — technically not a GLP-1, but the most common stack partner). This page is the master comparison — mechanism, trial data, dose, side effects, PH pricing, and which to choose for your protocol.
TL;DR — master comparison table
| Dimension | Tirzepatide | Retatrutide | Cagrilintide |
|---|---|---|---|
| Receptor targets | GIP + GLP-1 | GIP + GLP-1 + Glucagon | Amylin + Calcitonin |
| Class | Dual incretin agonist | Triple agonist | Amylin analogue |
| Peak weight loss | ~22.5% / 72 weeks | ~24.2% / 48 weeks | ~10.8% / 26 weeks |
| Trial stage | Phase 3 complete | Phase 3 ongoing | Phase 3 ongoing |
| Dose at peak | 15 mg weekly | 12 mg weekly | 2.4 mg weekly |
| Side-effect profile | Standard incretin GI | GI + transient HR rise + sweating | Mild; lowest GI burden |
| PH availability | Wide | Limited supplier base | Available; smaller supplier base |
| Noki Labs price | ₱2,000–₱3,500 | ₱2,500–₱3,200 | ₱2,200 |
| Best for | First-time GLP-1 users | Maximum efficacy | Tolerability + stack partner |
Mechanism — quickly
Tirzepatide: dual incretin amplification
Activates GIP and GLP-1 receptors simultaneously, amplifying post-meal insulin response, slowing gastric emptying, and reducing hypothalamic appetite drive. Weekly dosing, ~5-day half-life. The molecule sets the modern benchmark for incretin therapy.
Retatrutide: triple receptor recruitment
Adds glucagon agonism to the GIP/GLP-1 platform, recruiting hepatic energy expenditure and lipolysis on top of appetite reduction. The result is the steepest weight-loss curve documented in modern peptide research. Slightly hotter side-effect profile from the glucagon component.
Cagrilintide: amylin pathway, no incretin overlap
A long-acting amylin analogue that signals satiety, slows gastric emptying, and suppresses post-prandial glucagon — mechanically independent of GIP/GLP-1. Modest mono-effect (~10.8%) but exceptional GI tolerability and clean stack compatibility.
Clinical evidence side-by-side
SURMOUNT-1 (Tirzepatide): Jastreboff et al., NEJM 2022 — 20.9% mean weight reduction at 15 mg over 72 weeks.
TRIUMPH-1 (Retatrutide): Jastreboff et al., NEJM 2023 — 24.2% at 12 mg over 48 weeks, with no plateau yet visible.
Lau et al. (Cagrilintide): Lancet 2021 — 10.8% at 2.4 mg over 26 weeks.
CagriSema phase 2 (analog stack): Frias et al., Lancet 2023 — 15.6% at 32 weeks for cagri+sema, supporting the rationale for Tirzepatide+Cagrilintide stacking.
Cost in the Philippines
Reference prices: Atlas Compounds Retatrutide ~₱7,899/vial, MedsGo Tirzepatide ~₱5,985/vial. Noki Labs is the lowest-cost verified-COA option in the Philippines for all three.
| Compound | Noki Labs | Reference market | 12-week cost (Noki) |
|---|---|---|---|
| Tirzepatide 10 mg | ~₱2,800 | ₱5,985 | ~₱16,800 |
| Retatrutide 10 mg | ~₱2,900 | ₱7,899 | ~₱17,400 |
| Cagrilintide 10 mg | ₱2,200 | n/a | ~₱8,800 |
Apply BULK20 on stack orders over ₱15,000 for 20% off, or CLINIC15 on ₱10k+ orders.
Side effects — cross-comparison
Tirzepatide: classic incretin profile — nausea (peak weeks 2–6 each titration), occasional vomiting, mild constipation. Retatrutide: incretin profile plus glucagon-driven HR rise (3–7 bpm) and occasional sweating. Cagrilintide: by far the mildest — mild nausea at top dose, occasional injection-site redness, no cardiovascular signal.
Decision framework — which to choose
First-time GLP-1 individual
Tirzepatide. Densest dosing literature, well-mapped side-effect profile, forgiving titration. See /pages/tirzepatide-philippines.
Maximum-efficacy individual
Retatrutide — willing to ride the steepest curve at the cost of less mature long-term data. See /pages/retatrutide-philippines.
GI-sensitive individual
Cagrilintide solo or as a stack partner. See /pages/cagrilintide-philippines.
Plateau-breaker / advanced protocol
Tirzepatide + Cagrilintide stack. The most evidence-grounded peptide combination in modern weight-management research. See /pages/tirzepatide-cagrilintide-stack.
Budget-conscious
Cagrilintide standalone is the lowest per-cycle cost. Tirzepatide is the best efficacy-per-peso for serious weight-management protocols.
Head-to-head deep dives
- Tirzepatide vs Retatrutide
- Tirzepatide vs Cagrilintide
- Retatrutide vs Cagrilintide
- Tirzepatide + Cagrilintide stack
- AOD-9604 vs Tirzepatide
Where to buy in the Philippines
- /products/tirzepatide — ₱2,000–₱3,500, 4 variants
- /products/retatrutide — ₱2,500–₱3,200, 2 variants
- /products/cagrilintide — ₱2,200, 10 mg
Browse the weight-management collection for the full peptide lineup, or check the complete catalog. Manila customers, see /pages/peptide-supplier-manila.
FAQ
Q: Is Cagrilintide a GLP-1? No — it's an amylin analogue. Different class entirely, but commonly grouped because it's the standard GLP-1 stack partner.
Q: Which has the most data? Tirzepatide — phase-3 complete and replicated.
Q: Which has the steepest weight-loss curve? Retatrutide.
Q: Which is gentlest on side effects? Cagrilintide.
Q: Are these available in the Philippines? Yes — Noki Labs ships nationwide. We strongly recommend consulting a licensed healthcare provider familiar with peptide protocols before starting.
Always consult a licensed healthcare provider before starting any new peptide or wellness regimen. Individual results vary. Statements about our products are educational and not intended to diagnose, treat, cure, or prevent any disease.
Last reviewed: May 2026 · Read more in our FAQ